Breakthrough pain in cancer is an intense, sudden pain that is often unpredictable and debilitating and occurs despite otherwise appropriate opioid therapy, Archimedes Pharma reported.
During the rest of 2011, the company said Lazanda will be available through a Risk Evaluation and Mitigation Strategy program.
Read the FDA report on Lazanda.
Read the Archimedes Pharma release on Lazanda.
Related Articles on FDA Approvals:
FDA Clears New Version of PillCam for Esophageal Mucosa
Expected Approval of Minimally Invasive Aortic Devices Will Spark Boom
FDA Pressed to Speed Up Device OKs Before Fee Reauthorization
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.